Ipsen today announced the appointment of Harout Semerjian as President, Head of Specialty Care International Region & Global Franchises[1], effective February 2, 2017. He will report to David Meek, CEO of Ipsen, and will be a member of the Executive Leadership Team.
David Meek, CEO of Ipsen stated: “I am delighted to welcome Harout Semerjian to Ipsen. Harout brings extensive leadership experience in oncology and has achieved success across a diverse range of markets including the U.S., Europe and the Middle East. He will be a tremendous asset to Ipsen, particularly as we accelerate our growth across markets and strengthen our focus on speciality care and oncology.”
Harout has more than 23 years of pharmaceutical experience, including the last 17 years at Novartis focused on oncology and specialty care. He took on leadership roles with increasing responsibility across the U.S., Canada, Europe, Middle East & North Africa in addition to headquarter-based roles. His last role was Senior Vice President and Global Launch Head of ribociclib. Prior to that, he was Vice President and U.S. Hematology Franchise Head based in New Jersey.
Harout holds dual MBA degrees from Cornell University, New York and from Queen’s University, Canada. He also holds a Bachelor Degree of Science in Biology from the Lebanese American University.
[1] Including starting September 2017, Endocrinology Franchise activities related to Somatuline North America
